ICI-85966
Clinical data | |
---|---|
Other names | Stilbostat; Diethylstilbestrol (DES) bis(di(2-chloroethyl)carbamate) |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C28H34Cl4N2O4 |
Molar mass | 604.39 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
ICI-85966 (former tentative brand name Stilbostat), also known as diethylstilbestrol (DES) bis(di(2-chloroethyl)carbamate), is a synthetic, nonsteroidal estrogen and cytostatic antineoplastic agent of the stilbestrol group and a nitrogen mustard ester of diethylstilbestrol (DES) which was developed for the treatment of breast cancer and prostate cancer but was never marketed (possibly due to the toxicity of DES).[1][2][3][4][5]
See also
References
- ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 397. ISBN 978-1-4757-2085-3.
- ↑ Zimel H, Broder D, Zimel A (1973). "[Therapeutic effects of the preparation "Stilbostat" in advanced stages of breast cancer after the menopause]". Stud Cercet Endocrinol (in Romanian). 24 (3): 211–9. PMID 4703920.
- ↑ Görlich M, Heise E (1976). "Contribution to the mechanism of Stilbostat action". Neoplasma. 23 (4): 363–9. PMID 1004653.
- ↑ Zimel H, Mogos I, Maltezeanu G (1977). "Estimation of StilbostatR treatment efficiency in breast cancer by thermography". Neoplasma. 24 (5): 553–7. PMID 927612.
- ↑ Zimel H, Bocancea D (1974). "Treatment of prostatic carcinoma with Stilbostat". Neoplasma. 21 (1): 101–8. PMID 4596007.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.